Progress in cell cycle research最新文献_第3页

Airway smooth muscle cell hyperplasia: a therapeutic target in airway remodeling in asthma? 气道平滑肌细胞增生:哮喘气道重塑的治疗靶点?

Progress in cell cycle research Pub Date : 2003-01-01

Alaina J Ammit, Reynold A Panettieri

引用次数: 0

Rheumatoid arthritis: targeting the proliferative fibroblasts. 类风湿关节炎:靶向增殖性成纤维细胞。

Progress in cell cycle research Pub Date : 2003-01-01

Ijsbrand Kramer, Auragun Wibulswas, Daniel Croft, Elisabeth Genot

引用次数: 0

Cell cycle control in glomerular disease. 肾小球疾病的细胞周期控制。

Progress in cell cycle research Pub Date : 2003-01-01

Gunter Wolf, Stuart J Shankland

引用次数: 0

The mitotic checkpoint: a signaling pathway that allows a single unattached kinetochore to inhibit mitotic exit. 有丝分裂检查点:允许单个未附着着丝点抑制有丝分裂退出的信号通路。

Progress in cell cycle research Pub Date : 2003-01-01

Gordon K Chan, Tim J Yen

{"title":"The mitotic checkpoint: a signaling pathway that allows a single unattached kinetochore to inhibit mitotic exit.","authors":"Gordon K Chan, Tim J Yen","doi":"","DOIUrl":"","url":null,"abstract":"The mitotic checkpoint is a failsafe mechanism for the cell to ensure accurate chromosome segregation during mitosis. Mutations in genes encoding essential checkpoint proteins lead to chromosome instability and promote carcinogenesis. The BUB and MAD genes are essential components of the mitotic checkpoint pathway. BUB and MAD inhibit the ubiquitin ligase activity of the Anaphase Promoting Complex/Cyclosome (APC/C) during mitosis to ensure cells with unaligned chromosomes do not prematurely enter anaphase. Two models explain how the APC/C is inhibited by the checkpoint. The Sequestration Model postulates that Mad2 and BubR1 bind and sequester Cdc20, an APC/C activator, away from APC/C so substrates whose destruction drives mitotic exit are no longer ubiquitinated. In this model, the unattached kinetochore is postulated to catalytically convert Mad2 to a form that binds Cdc20. In the Direct Inhibition Model, the Mitotic Checkpoint Complex (MCC) consisting of BubR1, Bub3, Mad2 and Cdc20 binds and inhibits the APC/C independently of the kinetochore. However, the \"wait anaphase\" signal generated by unattached kinetochores sensitizes the APC/C to prolonged inhibition by the MCC. A single unattached kinetochore is proposed to amplify the \"wait anaphase\" signal through a kinase cascade involving checkpoint kinases such as hBubR1, hBub1 and Mps1.","PeriodicalId":79529,"journal":{"name":"Progress in cell cycle research","volume":"5 ","pages":"431-9"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24055423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The contemporary drug development process: advances and challenges in preclinical and clinical development. 当代药物开发过程:临床前和临床开发的进展和挑战。

Progress in cell cycle research Pub Date : 2003-01-01

Michelle D Garrett, Mike I Walton, Edward McDonald, Ian Judson, Paul Workman

{"title":"The contemporary drug development process: advances and challenges in preclinical and clinical development.","authors":"Michelle D Garrett, Mike I Walton, Edward McDonald, Ian Judson, Paul Workman","doi":"","DOIUrl":"","url":null,"abstract":"We are in a new era of drug discovery, in which it is feasible to develop therapeutic agents targeted at a particular protein or biological activity in a living cell. This has been made possible by major advances in our understanding of cell and molecular biology, epitomized by the 2001 Nobel prize award for Physiology or Medicine to Lee Hartwell, Tim Hunt and Paul Nurse, who were recognised for their work on key regulators of the cell cycle. Technological advances have also played a decisive role, leading to the sequencing of the human genome and increased throughput at many stages of the drug discovery and development process. For example, developments in high throughput screening, structural biology and microarray technology are increasing the speed of drug discovery. In this chapter we focus on the long, and often difficult, pathway which leads from identification of a hit in a screen to regulatory approval of a drug for disease treatment. The emphasis in this chapter is on the development of anticancer drugs, as this is our own area of expertise and also because cancer is a disease in which the cell cycle is already a major target for therapeutic intervention. However, many of the concepts, approaches and issues are generally common to other therapeutic areas.","PeriodicalId":79529,"journal":{"name":"Progress in cell cycle research","volume":"5 ","pages":"145-58"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24054408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proteomic approaches for the identification of cell cycle-related drug targets. 鉴定细胞周期相关药物靶点的蛋白质组学方法。

Progress in cell cycle research Pub Date : 2003-01-01

Mark R Flory, Ruedi Aebersold

引用次数: 0

The role of the replication licensing system in cell proliferation and cancer. 复制许可制度在细胞增殖和癌症中的作用。

Progress in cell cycle research Pub Date : 2003-01-01

S Shreeram, J Julian Blow